Johnson & Johnson Medical

Johnson & Johnson Medical is not clearly identifiable as a separately incorporated or consistently defined global brand in the supplied reference material. The name has historically been used in different markets and contexts for medical businesses connected with Johnson & Johnson, while the parent group’s current global medical-technology identity is Johnson & Johnson MedTech. It should therefore not be treated as a generic-pharmaceutical brand without further disambiguation. Johnson & Johnson is a United States healthcare group whose principal operating activities are organized around Innovative Medicine and MedTech. The medical-technology business develops, manufactures, and commercializes products used by hospitals, physicians, and other healthcare providers. Its areas include cardiovascular intervention, electrophysiology, heart recovery, surgery, orthopaedics, vision care, and other procedural specialties. Products are generally sold through healthcare institutions, distributors, clinicians, and specialized channels rather than through ordinary consumer retail. The medical operation’s positioning is based on clinical evidence, procedural innovation, workflow integration, physician education, and long-term relationships with hospitals and healthcare systems. Its portfolio includes technology acquired from and developed through businesses such as Biosense Webster, Abiomed, Shockwave Medical, and V-Wave. These businesses address conditions including atrial fibrillation, coronary and peripheral artery disease, heart failure, and surgical or orthopaedic needs. Recent portfolio development has emphasized cardiovascular intervention and other higher-growth medical-technology categories. Johnson & Johnson completed the acquisition of Shockwave Medical in 2024, bringing intravascular lithotripsy technology for calcified coronary and peripheral arteries into Johnson & Johnson MedTech. It also completed the acquisition of V-Wave in 2024, adding the Ventura interatrial shunt platform for heart-failure treatment. These transactions complemented the earlier acquisition of Abiomed and illustrate a strategy of concentrating resources on specialized technologies with potential to improve clinical outcomes. The supplied materials also refer to Johnson & Johnson’s broader pharmaceutical business, including the Carvykti cell therapy, Darzalex, and Tremfya. Those products belong to the group’s Innovative Medicine activities rather than establishing that “Johnson & Johnson Medical” is a pharmaceutical brand. The reference to the first direct-to-consumer Carvykti advertisement in 2025 is consequently recorded as a parent-company campaign, not as evidence that this ambiguous name represents a generic-drug portfolio. Because no single authoritative article or corporate page was supplied that defines Johnson & Johnson Medical as a distinct legal entity, product brand, or historical division, this entry preserves the name while flagging it for review. A future edition should determine whether the intended subject is Johnson & Johnson MedTech, a national subsidiary formerly using the Johnson & Johnson Medical name, or another Johnson & Johnson healthcare business.

The supplied evidence does not establish a distinct founding date, legal incorporation, or continuous corporate history for a standalone entity called Johnson & Johnson Medical. The name appears to function as an umbrella or regional designation connected with Johnson & Johnson’s healthcare and medical businesses. In the group’s current structure, the closest identifiable global subject is Johnson & Johnson MedTech, the operating organization responsible for medical technologies. Johnson & Johnson’s medical activities developed alongside the wider company’s expansion from healthcare products into hospital technologies, surgery, orthopaedics, cardiovascular care, electrophysiology, and vision care. Over time, the business combined internal research and development with acquisitions of specialist companies. This model allowed Johnson & Johnson to enter technically demanding categories where products require regulatory approval, clinical evidence, physician training, and hospital adoption. Cardiovascular technology has become a particularly visible part of the modern medical portfolio. Abiomed expanded the group’s heart-recovery capabilities, while Biosense Webster provides electrophysiology technologies used in the treatment of cardiac rhythm disorders. In 2024, Johnson & Johnson completed its acquisition of Shockwave Medical. Shockwave’s intravascular lithotripsy system uses sonic-pressure technology to modify calcified arterial plaque and is intended for coronary and peripheral vascular procedures. The transaction placed Shockwave within Johnson & Johnson MedTech and broadened the group’s cardiovascular-intervention presence. Later in 2024, Johnson & Johnson completed the acquisition of V-Wave. The company’s Ventura interatrial shunt was designed as a minimally invasive approach for selected heart-failure patients. V-Wave became part of Johnson & Johnson MedTech, adding a structural-heart and heart-failure platform to the group’s cardiovascular strategy. The parent group has also reorganized its wider portfolio. Consumer-health activities were separated into a distinct company, while Johnson & Johnson continued to focus on Innovative Medicine and MedTech. This reorganization makes it especially important to distinguish the ambiguous “Johnson & Johnson Medical” label from both the pharmaceutical business and consumer brands historically associated with Johnson & Johnson. Marketing in the medical business is primarily professional and evidence based. It uses clinical data, procedure demonstrations, healthcare-professional education, hospital relationships, and digital resources. The supplied material describes broader Johnson & Johnson campaigns involving physician outreach, patient education, real-world evidence, and specialized digital engagement. These approaches are relevant to the group’s healthcare model, but they do not prove that every campaign was run under a separate Johnson & Johnson Medical brand. The available material does not support a reliable account of a standalone “Johnson & Johnson Medical” brand’s founding, leadership succession, product catalog, or financial performance. The subject should therefore remain marked for review until a precise national subsidiary, historical division, or intended MedTech article is identified.

• 2024

  Shockwave Medical acquisition completed

  [1]Johnson & Johnson Completes Acquisition of Shockwave Medicaljnj.com

  Shockwave Medical became part of Johnson & Johnson MedTech, adding intravascular lithotripsy technology for coronary and peripheral artery disease.

• 2024

  V-Wave acquisition completed

  [2]Johnson & Johnson Completes Acquisition of V-Wavejnj.com

  V-Wave joined Johnson & Johnson MedTech with its Ventura interatrial shunt platform for heart-failure treatment.

• 2024

  Proteologix acquisition completed

  [3]Johnson & Johnson completes acquisition of Proteologix, Inc.jnj.com

  Johnson & Johnson added Proteologix’s early bispecific-antibody pipeline for immune-mediated diseases to its Innovative Medicine activities.

Evidence-led medical technology for hospitals and healthcare professionals, with emphasis on cardiovascular intervention, procedural innovation, clinical education, and technology integration.

• Cardiovascular intervention

  Shockwave intravascular lithotripsy

  A catheter-based platform that uses sonic-pressure waves to disrupt or modify calcified plaque in arteries. It is used in coronary and peripheral vascular intervention and became part of Johnson & Johnson MedTech through the acquisition of Shockwave Medical.

• Heart-failure technology

  Ventura Interatrial Shunt

  An implantable interatrial shunt developed by V-Wave for minimally invasive treatment approaches in heart failure. The platform entered Johnson & Johnson MedTech when the V-Wave acquisition was completed in 2024.

• Electrophysiology

  Biosense Webster electrophysiology systems

  Mapping, navigation, ablation, and catheter technologies used by specialists to diagnose and treat cardiac rhythm disorders, including atrial fibrillation. Biosense Webster is part of Johnson & Johnson’s MedTech portfolio.

• Cardiac support

  Abiomed heart-recovery technologies

  Mechanical circulatory-support technologies associated with Abiomed and used in selected acute heart-failure and cardiac-procedure settings. Abiomed forms part of Johnson & Johnson’s cardiovascular medical-technology activities.

• 2025Carvykti direct-to-consumer streaming campaign

  United States

  Johnson & Johnson tested its first direct-to-consumer advertising for Carvykti, a CAR-T therapy for multiple myeloma, using streaming services to raise awareness among patients who may not be treated at specialist academic centers.

  Outcome. The campaign was presented as a sign of confidence that manufacturing capacity could support additional demand after earlier supply limitations.

  Source
• 2020Data-driven professional advertising for Listerine

  United States

  Johnson & Johnson used behavioral analysis of healthcare professionals to target digital advertising intended to encourage recommendations of the Listerine dental brand.

  Outcome. The cited case study reported professional-audience engagement substantially above an industry benchmark.

  Source

• 2024

  Acquire Shockwave MedicalM&A

  Background

  Johnson & Johnson sought to strengthen its cardiovascular-intervention portfolio with Shockwave’s intravascular lithotripsy technology.

  Action taken

  The acquisition was completed and Shockwave began operating as a business unit within Johnson & Johnson MedTech.

  Aftermath

  The transaction expanded the group’s cardiovascular platforms alongside heart-recovery and electrophysiology businesses.

  Source

• 2024

  Acquire V-WaveM&A

  Background

  The transaction was intended to deepen Johnson & Johnson MedTech’s presence in structural heart and heart-failure care.

  Action taken

  Johnson & Johnson completed the acquisition of V-Wave and placed it within Johnson & Johnson MedTech.

  Aftermath

  The Ventura interatrial shunt became part of the company’s developing heart-failure technology portfolio.

  Source

• 2019-10-28

  Johnson & Johnson Medical and TINAVI sign commercial and research agreement[6]强生医疗与天智航签署商业和研发协议prnasia.com

  Reported: 2019-10-28

  Johnson & Johnson (Shanghai) Medical Equipment Co., Ltd. and TINAVI signed a commercial and research agreement to bring TINAVI’s robotic solutions for spine and trauma surgery to more orthopedic doctors and patients in China.

1. 1Johnson & Johnson Completes Acquisition of Shockwave Medicaljnj.com
2. 2Johnson & Johnson Completes Acquisition of V-Wavejnj.com
3. 3Johnson & Johnson completes acquisition of Proteologix, Inc.jnj.com
4. 4J&J tests direct CAR-T marketing with first Carvykti adbiopharmadive.com
5. 5Data-driven professional advertising for Listerineeconsultancy.com
6. 6强生医疗与天智航签署商业和研发协议prnasia.com